zh-twzhen
zh-twzhen

News

2025

Date

Title

2025-11-12

Oneness Biotech Co., Ltd. receives a Canadian patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>
2025-11-11

The medical device registration application of Bonvadis for all indications of wounds has been accepted by Health Canada.

>
2025-11-10

The Company’s 2025Q3 consolidated financial statements have been approved by the Board of Directors

>
2025-10-27

The medical device registration application of Bonvadis for all indications of wounds has been accepted by Argentina National Administration of Drugs, Foods, and Medical Devices (ANMAT).

>
2025-10-03

The medical device registration application of Bonvadis for all indications in wounds has been accepted by ThaiFDA.

>
2025-10-03

The medical device registration application of Bonvadis for all indications of wounds has been accepted by COFEPRIS in Mexico.

>
2025-09-17

A Thailand patent on the Anti-CεmX (FB825) antibody was granted

>
2025-08-29

A U.S. patent titled ”METHODS FOR PREPARATION OF PLECTRANTHUS AMBOINICUS EXTRACTS” has been granted.

>
2025-08-28

Oneness has decided to discontinue the development of OB318 based on considerations of research and development efficiency.

>
2025-08-19

News-Promoting “Yellow Carbon”: Oneness Biotech and National Chung Hsing University Reveal Breakthroughs in Organic Farming Carbon Sequestration

>
2025-08-08

The Company’s 2025Q2 consolidated financial statements have been approved by the Board of Directors

>
2025-07-28

The medical device registration application of Bonvadis for all indications in wounds has been accepted by Morocco AMMPS.

>
2025-07-18

Fespixon, the new drug in treatment of diabetic foot ulcers has been approved by Indonesia BPOM and the drug license has been granted.rt-hit of stock trading in the security market.

>
2025-06-10

Mechanism of ON101 cream for prevention and treatment of radiation dermatitis has been published in the SCI journal, Life Sciences

>
2025-06-10

Today, Bonvadis is 510(k) cleared by the U.S. FDA for full-thickness chronic wounds, marking a significant milestone in international commercialization.

>